ECG
BBIO icon

EPIQ Capital Group’s BridgeBio Pharma BBIO Stock Holding History

EPIQ Capital Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$446K Sell
16,248
-4
-0% -$103 0.12% 49
2024
Q3 		$414K Buy
+16,252
New +$427K 0.12% 48

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

EPIQ Capital Group's BBIO Position: Q4 2024 in Review

EPIQ Capital Group reduced its BridgeBio Pharma (BBIO) stake by 0.02% in Q4 2024, selling an estimated $103 and leaving 16,248 shares worth $446K. The position accounts for 0.12% of the portfolio, ranked #49.

EPIQ Capital Group first reported a position in BBIO in Q3 2024 and has held it in 2 quarters since. 263 funds tracked by Wall St. Rank hold BBIO as of Q4 2024.

  • EPIQ Capital Group held 16,248 shares of BridgeBio Pharma worth $446K as of Q4 2024.
  • EPIQ Capital Group sold 4 BridgeBio Pharma shares in Q4 2024, an estimated $103.
  • BridgeBio Pharma made up 0.12% of EPIQ Capital Group's portfolio in Q4 2024, its #49 holding.
  • EPIQ Capital Group first reported a position in BridgeBio Pharma in Q3 2024 and has held it in 2 quarters since.
  • 263 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2024.

Based on EPIQ Capital Group's 13F filing for Q4 2024, filed 7 Feb 2025.